XBiotech posts results for XB2001 pancreatic cancer trial, over five years after registration
Results for the Phase I/II "1-BETTER" trial testing XB2001 with ONIVYDE and 5-FU/LV in advanced pancreatic cancer were posted in August 2026, more than five years after the study was first registered.
XBiotech's main update of the week concerns a completed pancreatic cancer trial whose results appeared roughly five years and four months after the study was first listed.
- Phase I/II trial "1-BETTER" (NCT04825288) tested XB2001, an anti-IL-1⍺ True Human Antibody, in combination with ONIVYDE plus 5-FU/LV in advanced pancreatic cancer.1 The study was first posted on 2021-04-01, reached study completion on 2025-06-10, and had results first posted on 2026-08-04. Enrollment reached 76 participants across a randomized, interventional design spanning phase 1 and phase 2.1 The phase 1 portion tested three dose levels of 250 mg, 500 mg, and 1000 mg using a traditional 3:3 escalation design,1 while phase 2 randomized patients to receive either XB2001 1000 mg or placebo, both combined with ONIVYDE, leucovorin, and 5-Fluorouracil.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.